Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients
A novel approach to treating cancer in the settings of Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) is the use of a subcutaneous (SC) injection of Rituximab (in addition to standard combination chemotherapy). Alberta cancer patients can safely benefit from the administration o...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pappin Communications
2015-07-01
|
| Series: | Canadian Oncology Nursing Journal |
| Subjects: | |
| Online Access: | http://www.canadianoncologynursingjournal.com/index.php/conj/article/view/580/578 |